Home › Funds › Trails Edge Capital Partners, LP › NGNE
Trails Edge Capital Partners, LP position in NGNE
NEUROGENE INC COM · Health Care
Trails Edge Capital Partners, LP reported holding 714,885 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$22.5M, representing 3.57% of its reported portfolio and ranking #13 among its reported holdings. Trails Edge Capital Partners, LP has disclosed NGNE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's NGNE position evolved
Trails Edge Capital Partners, LP first disclosed a stake in NGNE in Q4 2025 at 785,000 shares (US$16.2M). The position peaked in Q2 2026 at 714,885 shares, worth US$22.5M. Across 3 filings, Trails Edge Capital Partners, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 714,885 shares valued at US$22.5M — a reduction of -67,902 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 785.00K | $16.17M | New |
| Q1 2026 | 782.79K | $15.78M | Hold |
| Q2 2026 | 714.88K | $22.48M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), Redmile Group, LLC (US$44.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.72M sh · $54.00M · Q2 2026
- Casdin Capital 1.55M sh · $48.60M · Q2 2026
- Redmile Group, LLC 1.41M sh · $44.41M · Q2 2026
- RTW INVESTMENTS, LP 1.36M sh · $42.85M · Q2 2026
- EcoR1 Capital, LLC 1.27M sh · $39.98M · Q2 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $31.19M · Q2 2026
- GREAT POINT PARTNERS LLC 352.18K sh · $11.08M · Q2 2026
- DAFNA Capital Management LLC 89.03K sh · $2.80M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held NGNE?
Trails Edge Capital Partners, LP has disclosed NGNE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Trails Edge Capital Partners, LP's current position in NGNE?
As of Q2 2026, Trails Edge Capital Partners, LP holds 714.88K shares of NGNE (NEUROGENE INC COM), valued at $22.48M, representing 3.57% of its reported portfolio and ranking #13.
Has Trails Edge Capital Partners, LP been buying or selling NGNE?
In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP reduced its position in NGNE. The position peaked in Q2 2026 at 714.88K shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.